infants at highest risk of RSV

How to Order SYNAGIS®

SYNAGIS is only available for order through approved 
Specialty Pharmacy Networks and Specialty Distributors

Infants at highest risk RSV

Specialty Pharmacy Networks

For Continental US the Specialty Pharmacy network is open.

For Physician Offices, please verify with the patient’s plan or Pharmacy Benefit Manager (PBM) which Specialty Pharmacies are in a plan's network and allowed to dispense.

For Puerto Rico please use:

Special Care Pharmacy Services
Address: 55 Arzuaga Street, San Juan, PR 00925
Phone: 787-781-4585
Toll-free Number: 877-899-8997 or 888-727-1727
Fax: 787-783-2951 or 855-230-9963

Specialty Distributors

For Specialty Pharmacies and Institutions

ASD HealthCare

Phone: 800-746-6273
Fax: 800-547-9413
Email: asd.customerservice@asdhealthcare.com
Web: asdhealthcare.com

Cardinal Health Specialty Pharmaceutical Distribution

Ordering information for hospitals, specialty pharmacies and retail independent pharmacies:
Phone: 855-855-0708 (hospitals)
Phone: 866-677-4844 (specialty & retail pharmacy)
Web: orderexpress.cardinalhealth.com

Cardinal Health Puerto Rico (Puerto Rico and US Territories)

Phone: 800-981-4699 or 787-625-4200
Fax: 787-625-4398
Email: cuserv@cardinalhealth.com
Online via Order Express: orderexpress.cardinalhealth.com
Online via Specialty Health: specialtyonline.cardinalhealth.com

CuraScript SD

Phone: 877-599-7748
Fax: 800-862-6208
Email: Customer.Service@curascript.com
Web: curascriptsd.com

McKesson Plasma and Biologics

Phone: 877-625-2566
Fax: 888-752-7626
Email: mpborders@mckesson.com
Web: connect.mckesson.com

McKesson Specialty Care Distribution

Phone: 855-477-9800
Email: msh.customercare-mspl@mckesson.com
Web: mscs.mckesson.com/CustomerCenter

All imagery is for illustrative purposes only.

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

  • with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
  • with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
  • with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

Limitations of Use

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

  • with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
  • with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
  • with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

Limitations of Use

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

Contraindications

Previous significant hypersensitivity reaction to SYNAGIS.

Warnings and Precautions

Hypersensitivity Reactions: Anaphylaxis and anaphylactic shock (including fatal cases) and other severe acute hypersensitivity reactions have been reported. Permanently discontinue SYNAGIS and administer appropriate medication if such reactions occur.

Coagulation Disorders: SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder.

RSV Diagnostic Test Interference: Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Adverse Reactions

Serious Adverse Reactions: The most common serious adverse reactions occurring with SYNAGIS are anaphylaxis and other acute hypersensitivity reactions.

Most Common Adverse Reactions: The most common adverse reactions are fever and rash.

Postmarketing Experience: Severe thrombocytopenia and injection site reactions have been identified during post approval use of SYNAGIS. 
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These are not all the possible risks associated with SYNAGIS. Please see full Prescribing Information for SYNAGIS, including Patient Information. To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or the FDA at 1-800-FDA-1088.

For statutory pricing disclosures, visit https://www.sobi.com/usa/en/state-disclosure-requirements